Evidence map›Paper›PMID 41970240›Full record

ArticleWellcome open research2024

Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults.

Daniel Silman, Amy Flaxman, Mehreen Datoo, Nick J Edwards, Fernando Ramos-Lopez, Celia Mitton, Catherine Mair, Duncan Bellamy, Georgina Bowyer, Richard Morter and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Wellcome open research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Daniel SilmanJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.
Amy FlaxmanJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.ORCID https://orcid.org/0000-0001-6460-1372
Mehreen DatooJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.ORCID https://orcid.org/0000-0003-4968-2842
Nick J EdwardsJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.
Fernando Ramos-LopezJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.
Celia MittonJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.
Catherine MairJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.
Duncan BellamyJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.
Georgina BowyerJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.
Richard MorterJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.
Benedict HalbrothJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.
Navin VenkatramanJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.
Pedro M FolegattiJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.
Julia MarshallJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.
Ian PoultonJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.ORCID https://orcid.org/0000-0002-6603-8461
Amelia BajerJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.ORCID https://orcid.org/0000-0003-1616-2373
Ahmed M SalmanJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.
Eleanor BerrieClinical Biomanufacturing Facility, University of Oxford, Churchill Hospital, Oxford, England, OX3 7JT, UK.
Jake BaumDepartment of Life Sciences, Imperial College London Faculty of Natural Sciences, London, England, SW7 2AZ, UK.
Andrew M BlagboroughDepartment of Life Sciences, Imperial College London Faculty of Natural Sciences, London, England, SW7 2AZ, UK.
Wendy CrockerJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.
Rachel RobertsJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.
Alison M LawrieJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.
Alexandra J SpencerJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.ORCID https://orcid.org/0000-0001-7958-6961
Sarah C GilbertJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.ORCID https://orcid.org/0000-0002-6823-9750
Katie J EwerJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.ORCID https://orcid.org/0000-0001-9827-9836
Adrian V S HillJenner Institute, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford Nuffield Department of Medicine, Oxford, England, OX3 7DQ, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Induction of CD8 Methods: We conducted a non-randomised, open-label, dose escalation phase I/IIa study in UK adults, vaccinating a small lead-in group with ChAdOx1 LS2 5x10 Results: Vaccination with ChAdOx1 LS2 (both low and full doses) and MVA LS2 were generally well tolerated with solicited symptoms observed similar to previous vectored vaccines and no Severe Adverse Events (SAEs). Immunogenicity of the prime-boost schedule as measured by IFN-γ ELISpot was high showing median response of 4473 SFC/10 Conclusions: Though this study further indicates ChAd/MVA as a safe, highly effective platform for driving CD8

Indexed as

P. falciparum; malaria; vaccines; CHMI; T cells; adenovirus; MVA; viral vectors

Identifiers

PMID41970240
PMCPMC13066805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.